Top

Reactions Weekly

Published in:

01-03-2024 | Infliximab | Case report

Infliximab/Nivolumab

Acute exacerbation of idiopathic pulmonary fibrosis and lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Irons C, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Patient With Lung Cancer on Immunotherapy and After Video-Assisted Thoracoscopic Surgery. American Journal of Respiratory and Critical Care Medicine 207: A3212, May 2023. Available from: URL: https://dx.doi.org/10.1164/ajrccm-conference.2023.B37 [abstract]

Title: Infliximab/Nivolumab
Acute exacerbation of idiopathic pulmonary fibrosis and lack of efficacy
Publication date: 01-03-2024
Publisher: Springer International Publishing
Keywords: Infliximab
Idiopathic Pulmonary Fibrosis
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-54115-y

At a glance: The STEP trials

Springer Medicine

Infliximab/Nivolumab

Acute exacerbation of idiopathic pulmonary fibrosis and lack of efficacy

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Infliximab

Theophylline

Cytarabine

Hydralazine

Antineoplastics

Ruxolitinib